All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
What is the clinical value and potential of momelotinib for anemic patients with myelofibrosis?
Bookmark this article
During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to Abdulraheem Yacoub, University of Kansas Medical Center, Kansas City, US, about anemia in myelofibrosis (MF). We asked, What is the clinical value and potential of momelotinib for anemic patients with MF, and how does it compare to other JAK inhibitors (JAKi)?
What is the clinical value and potential of momelotinib for anemic patients with myelofibrosis?
Anemia is a hallmark of MF and can also be a prognostic factor, with severe anemia indicating severe disease and therefore a poorer outcome. Anemia is responsible for high symptom burden in patients with MF. Many of the current treatments for MF can increase the severity of anemia, and therefore this indicates a clear unmet need for novel therapies.
Your opinion matters
20 votes - 79 days left ...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox